Ischaemic heart disease is a leading cause of mortality. After ischaemic injury, tissue hypoxia induces the activity of angiogenic factors that promote revascularization. Increased understanding of hypoxia-responsive genes and their role in angiogenesis will lead to new therapies for ischaemic injury. We delineated the function of Canopy 2 (CNPY2), a newly discovered, hypoxia-regulated gene.
Introduction
Under conditions of inadequate perfusion or oxygenation, tissues can frequently compensate by increasing vascularization, protecting themselves from the harmful effects of hypoxia and ischaemia.
1 Neovascularization is important for restoring blood flow and allowing the heart to heal after injury, such as a myocardial infarction, and is often triggered by tissue hypoxia. Cell signalling plays a major role in the process of revascularization, and although many secreted angiogenic factors required for this process have been discovered, many more remain to be determined. Cells challenged with hypoxia activate the global transcription factor HIF-1a, which differentially regulates the transcription of a variety of target genes, 2 some of which might play important yet unidentified roles in growth, angiogenesis, and other physiological and pathological processes. We performed a PCR screen on genes that encode putative secreted proteins predicted from a previous study 3 in primary human smooth muscle cells (SMCs) following exposure to hypoxia. We identified several transcripts that were up-regulated by hypoxia, including Canopy 2 (CNPY2), which encodes a member of the Canopy family of proteins (which includes CNPY1 -4) and belongs to a larger protein superfamily called the saposin-like proteins (SAPLIPs). 4 All of the Canopy proteins (1-4) have a similar domain structure, containing a consensus signal peptide, a saposin B-type domain, and an endoplasmic reticulum (ER) retrieval sequence but no hydrophobic transmembrane domains. Most SAPLIPs function by interacting with the lipids that make up the cell membrane, but the protein structure of the CNPYs diverges significantly from that of other SAPLIPs, so whether the CNPY proteins exert their functions by interacting with lipids is unknown. It is clear, however, that the CNPY proteins are involved in cell signalling. For instance, CNPY1 has been shown to be a positive feedback regulator of FGF signalling by binding the extracellular domain of FGFR1 in zebrafish, but not the intracellular domain, which controls progenitor cell clustering during Kupffer's vesicle organogenesis. 5 CNPY3 and CNPY4 (also called PRAT4A and PRAT4B) associate with toll-like receptors 4 and 1 to regulate their cell surface expression and the cellular immune response. 6 -8 CNPY2 has several names in GenBank [Putative Secreted Protein Zsig9, Transmembrane protein 4 (TMEM4), HP10390, and MIRinteracting saposin-like protein (MSAP)], but there are only few studies that have evaluated its biological function. When ectopically overexpressed by transfecting cells with its expression construct, CNPY2 was reported to enhance neurite outgrowth in neuroblastoma and PC12 cells, and to enhance cell spreading in fibroblasts and migration of rat C6 glioma cells through phosphorylation of myosin regulatory light chain (MRLC) and preventing MIR-mediated MRLC ubiquitination and its subsequent proteasomal degradation. 9, 10 CNPY2 was also shown to influence the expression of low-density lipoprotein receptor and FGF21. 11 In the present study, we provide additional information that CNPY2 is a transcriptional target of HIF-1a, and CNPY2 encodes a secreted protein that stimulates SMC proliferation and migration and enhances angiogenesis.
Methods
For a complete description of the methods used, pleased see Supplementary methods online.
Human SMC culture, RT -PCR, and real-time PCR
Primary human vascular SMCs were isolated from vascular segments obtained with informed consent from three independent patient donors undergoing bypass surgery at Toronto General Hospital (n ¼ 3/experimental condition, with each replicate coming from a different donor). These cells were used at Passage 3. The protocol was approved by the Research Ethics Board of the University Health Network, in accordance with the Declaration of Helsinki. The SMCs were cultured under normoxia or hypoxia (0.2% O 2 ) and their RNA extracted. RT -PCR and real-time PCR were used to compare the concentration of CNPY2 mRNA in both conditions, relative to the gene encoding b-actin.
2.2 ELISA detection, immunoprecipitation of secreted CNPY2 protein, siRNA knockdown, and western blotting ELISA was used to determine the concentration of CNPY2 found in SMC culture medium after incubation under normoxia and hypoxia, and in the blood of healthy mice and humans. Secreted CNPY2 was immunoprecipitated by a rabbit-anti-CNPY2 antibody from SMCs grown in normoxia, or after 24 -48 h of hypoxia, using recombinant CNPY2 expressed from Escherichia coli as a positive control as we recently described. 12 To test for activation of factors related to cell mobility, SMCs stimulated with recombinant CNPY2 protein were lysed and western blotted, with antibodies against phospho-FAK Tyr 397 , Tyr 861 , Tyr 925 , total FAK, phosphor-PAK1, and total PAK. To examine activation of RhoA, Rac1, and Cdc42, SMC cell lysates from cultures stimulated with CNPY2 and grown under conditions of normoxia or hypoxia were incubated with agarose beads coupled to a Rho binding domain peptide (for RhoA) or the p21 binding domain of PAK1
(for Rac1 and Cdc42) and then western blotted with Rho-, Rac1-, or Cdc42-specific antibodies. SMCs were treated with prolyl-4-hydroxylase inhibitor dimethyloxalylglycine (DMOG, a HIF-1a activator) 13,14 for 6 h or under hypoxia for 24 h, or were transfected with control siRNA or siRNA against HIF-1a for 24 h and then stimulated by hypoxia for 24 h. Cell lysates were probed with both HIF-1a and CNPY2 antibodies for protein expression.
Chromatin immunoprecipitation and chimeric luciferase constructs
Cultured SMCs were subjected to hypoxia for 1, 2, 3, 4, 6, 9, 24, or 48 h, and HIF-1a binding to the CNPY2 upstream region was examined by chromatin immunoprecipitation (ChIP). Anti-RNA polymerase antibody and normal mouse IgG were used as positive and negative controls, respectively, for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) PCR amplification. Detailed cloning strategies for HRE constructs are outlined in Supplementary material online, Table S2 . A 75 bp sequence harbouring the core hypoxia response element (HRE-1157 bp upstream of the transcription start site, TSS, of CNPY2) was cloned as an enhancer in a luciferase pGL4.27 vector with a minimal promoter. An identical construct except for a scrambled core HRE was used as a negative control. A 1192 bp genomic DNA fragment harbouring HRE-1157 followed by the endogenous human CNPY2 promoter region was also cloned in a luciferase pGL4.22 promoterless vector to verify the potential influence of HRE-1157 on CNPY2 promoter activity under hypoxia. These constructs were transfected into HEK293 cells, and the luciferase activity was measured.
2.4
In vitro SMC proliferation, cytotoxicity, immunocytochemistry, and migration assays SMC proliferation with and without stimulation with recombinant CNPY2 (see Supplementary material online, Figure S1A ) was measured using an MTT assay and cell counting. Cytotoxicity of SMCs grown under conditions of hypoxia and normoxia was measured using a lactate dehydrogenase release assay. To examine SMC polarization after stimulation with CNPY2 or vehicle control, cells were stained with an anti-vimentin antibody and phalloidin to show F-actin. For CNPY2 subcellular localization, SMCs were treated with or without Brefeldin A and then stained with CNPY2 antibody and either an ER marker (protein disulfide isomerase) or a Golgi marker (Golgi 58 K protein). For the scratch wound-healing assay, a scratch was made in a growing SMC culture. CNPY2 protein or vehicle control buffer was added, and the total numbers of cells that have migrated after 15 h across pre-drawn lines at the bottom of culture dish were counted. For the transwell migration assay, SMCs were seeded into the top insert wells and vehicle control buffer, or 10 nM CNPY2 protein was added to the lower chamber. The number of migrating cells that crossed the membrane was determined.
Rat ex vivo aortic ring sprouting assay
Thoracic aortas were excised from rats and dissected into 1 mm crosssections (n ¼ 4 per experimental group, with all 12 rings derived from a single animal). Aortic rings were stimulated every other day with 10 nM of recombinant CNPY2 or VEGF protein, and images were taken and analysed for total sprouting area on Day 6. Another set of aortic rings (n ¼ 4 per experimental group, also derived from a single animal) was then fixed and stained with antibodies against a-SMA (to show SMCs) and von Willebrand Factor (to show endothelial cells, ECs).
Mouse retinal ischaemia/reperfusion model
The anterior chambers of the eyes of mice were cannulated and subjected to hydrostatic pressure to induce retinal ischaemia, which was confirmed by whitening of the iris and loss of the red reflex. The needle was withdrawn and the intraocular pressure normalized, resulting in a reperfusion injury, which was confirmed by the reappearance of the red reflex. CNPY2
protein (25 ng) or saline was injected intravitreally immediately after ischaemia -reperfusion injury. Five days later, the mice were euthanized, and the isolated mouse retinae were stained with Alexa Fluor-568 Isolectin GS-IB4 conjugate to visualize the vasculature. Total isolectin-positive area and total length of vascular structures were measured and normalized to total retinal area. Vessel branching was also quantified.
Statistical analysis
Data are presented as mean + SEM. Student's t-test was used for two-group comparisons. Comparisons of parameters among three groups or more were analysed by one-way ANOVA, followed by a Tukey post hoc test. Differences were considered statistically significant at a value of P , 0.05.
Results

CNPY2 transcript is regulated by hypoxia and encodes a secreted protein
Following a PCR screen in human SMCs under hypoxia, we identified several transcripts that are differentially regulated by hypoxia (see Supplementary material online, Figure S1B ), and we focused on CNPY2 in the present study. Semi-quantitative PCR shows that CNPY2 was transiently up-regulated by 24 h of hypoxic stimulation ( Figure 1A ). VEGF served as a positive control, and b-actin served as a loading control. Quantitative real-time PCR with a TaqMan probe revealed that CNPY2 mRNA in SMCs was up-regulated 1.5-fold after 24 h and 2-fold after 48 h of hypoxic stimulation ( Figure 1B ). Immunostaining demonstrated that CNPY2 protein was expressed throughout the whole cytoplasm of SMCs, and some CNPY2 also co-localized with ER and Golgi compartments. Interestingly, after treatment with Brefeldin A, which destroys the Golgi stacks and blocks protein transport from the ER to the Golgi complex, 15 CNPY2 protein accumulated in the ER compartment and no longer co-localized with the Golgi marker ( Figure 1C ). CNPY2 has a typical N-terminal signal peptide and no hydrophobic transmembrane domains (GenBank accession no. NP_055070) and has been predicted to be a secreted protein by SignalP 4.1 (http:// www.cbs.dtu.dk/services/SignalP/) and TMHMM v. 2.0 (http://www. cbs.dtu.dk/services/TMHMM/). We show that CNPY2 co-localized to the ER and Golgi compartments, where secreted proteins are usually processed. 16 This prompted us to investigate whether CNPY2 is secreted from cultured SMCs. As shown in Figure 1D by ELISA, CNPY2 was found to be secreted into the culture medium of SMCs under normoxia, with increasing concentrations seen after 24-and 48-h hypoxic stimulation. No significant change in LDH release from SMCs was seen under hypoxia compared with normoxia, indicating the CNPY2 found in the SMC culture medium was not due to cell death and lysis upon hypoxic challenge ( Figure 1E ). Moreover, secreted CNPY2 was also detected by ELISA in the serum of healthy humans (85.3 + 19.6 pg/ml, n ¼ 8, age 25-50 years) and mice (117.3 + 5.5 pg/ml, n ¼ 15, age 6-8 weeks).We further showed that CNPY2 is secreted from cultured SMCs by immunoprecipitating it from culture medium using the CNPY2 antibody. A western blot re-probed with the antibody showed a faint but distinct CNPY2 band that was pulled down from SMC medium under normoxia, which increased after 24-and 48-h hypoxic stimulation ( Figure 1F ). Native CNPY2 protein from SMC culture medium was a similar size as recombinant His-CNPY2 protein purified from E. coli ( 20 kDa). CNPY2 was not present in the control medium (medium not used for cell culture) stored under normoxia or hypoxia. Taken together, our data demonstrate that CNPY2 encodes a secreted protein, and its transcription is up-regulated in SMCs by in vitro hypoxia, resulting in increased CNPY2 protein present in the culture medium after hypoxic stimulation.
CNPY2 transcription is controlled by HIF-1a
Since the CNPY2 transcript is up-regulated in vitro by hypoxia in SMCs, we wondered whether HIF-1a expression correlates with CNPY2 expression. As shown in Figure 2A by western blot, in the SMCs under 24-h hypoxia or stimulated with a prolyl-4-hydroxylase inhibitor DMOG for 6 h (which stabilizes HIF-1a under conditions of normoxia), 13, 14 increased levels of CNPY2 protein expression were observed compared with normoxia. Conversely, when the endogenous HIF-1a was first silenced by siRNA and then stimulated with 24-h hypoxia, CNPY2 protein level also decreased, correlating with the decreased HIF-1a protein level ( Figure 2B ). As illustrated in Figure 2C , we found several putative HREs upstream of human CNPY2 promoter region. We designed PCR primers to amplify small fragments harbouring each HRE (see Supplementary material online, Table S1 ). Cultured cells were subjected to hypoxia for 1-48 h before incubation with a crosslinking agent. Genomic DNA was sheared by sonication and immunoprecipitated with a ChIP-grade anti-HIF-1a antibody. Anti-RNA polymerase antibody and normal mouse IgG were used as positive and negative controls, respectively, and used to immunoprecipitate DNA associated with the GAPDH gene. As shown in Figure 2D , ChIP-PCR bands corresponding to HRE-1157 could be detected after as little as 1-h hypoxic stimulation, peaking at 3-6 h, and were sustained until 24 h. No specific bands could be detected with the other three putative HREs (data not shown). A hypoxia time course also stabilized the HIF-1a protein, compared with the nearly undetectable levels seen under normoxic conditions ( Figure 2E ). This indicates that, upon hypoxic stimulation, HIF-1a can bind the HRE 1157 bp upstream of the predicted CNPY2 promoter region and regulate CNPY2 transcription. Next, we created a chimeric luciferase construct, in which a 75 bp sequence centred on the core HRE-1157 was cloned between the XhoI and BglII restriction sites in the pGL4.27 vector, as an 'enhancer' element in front of the luciferase cDNA driven by a minimal promoter ( Figure 2F ). We used an identical construct except for a scrambled core HRE-1157 sequence as a control (see Supplementary material online, Table S2 ). The HRE or mutant construct was transiently transfected into HEK293 cells for 24 h and then subjected to hypoxia. Increasing luciferase activity was observed when cells were challenged by hypoxia in cells transfected with the HRE-1157 construct, while the mutant did not show this response ( Figure 2G ). In addition, a 1192 bp genomic DNA fragment including HRE-1157 and followed by the predicted endogenous human CNPY2 promoter region was obtained and cloned between XhoI and BglII restriction sites in the pGL4.22 promoterless luciferase vector (see Supplementary material online, Table S2 ). Enhanced endogenous CNPY2 promoter activity was seen when this construct was transfected into HEK293 cells and then subjected to 24-or 48-h hypoxic stimulation compared with normoxia ( Figure 2H ). All of these data confirmed that the CNPY2 transcript is up-regulated in cultured SMCs upon hypoxic stimulation, due to the fact that CNPY2 is a target of HIF-1a.
CNPY2 induces SMC cytoskeleton polarization, migration, and proliferation
Previously, CNPY2 was reported to enhance cell spreading and migration in fibroblasts and rat C6 glioma cells transfected with a CNPY2 CNPY2 promotes angiogenesis expression construct. 9, 10 Our data show that CNPY2 is a secreted protein. We therefore investigated whether adding CNPY2 protein to SMC culture media could also promote migration. Vimentin is an intermediate filament protein that functions as an organizer of a number of critical factors involved in cell migration and signalling transduction. As shown in Figure 3A , SMCs exhibited their typical spindle shape with a central nucleus and with vimentin distributed evenly throughout the cytoplasm. After 15 min of CNPY2 stimulation, the cells showed ChIP followed by PCR detection demonstrated that, compared with the normoxia (N), HIF-1a binds the HRE 21157 bp upstream of the TSS in SMCs as early 1 h after exposure to hypoxia, peaking at 3 -6 h, and gradually decreased, but sustained PCR bands remained detectable up to 24 h. Anti-RNA polymerase II and normal mouse IgG with GAPDH primers served as positive and negative controls, respectively. (E) Hypoxia stabilized HIF-1a protein from 1 to 48 h under hypoxic conditions in SMCs. (F) Schematic of the chimeric luciferase expression constructs in which a 75 bp sequence centred on HRE-1157 in the middle were cloned in pGL4.27 vector as an 'enhancer' for binding by HIF-1a. The mutant construct was identical except the core HRE sequence was scrambled. A 1192 bp long sequence including HRE-1157 followed by the endogenous human CNPY2 promoter was cloned in pGL4.22 promoterless vector to assess the native CNPY2 promoter activity under hypoxia. Cloning details are provided in Supplementary material online, Table S2 . (G) Increasing luciferase activity was observed when HEK293 cells were challenged with hypoxia in HRE-1157/pGL4.27 construct-transfected cells, while the mutant showed no response (n ¼ 4, **P , 0.01). (H ) Increased luciferase activity was observed in HEK293 cells transfected with the HRE-1157/pGL4.22 construct under hypoxia (n ¼ 4, **P , 0.01), indicating that this endogenous human CNPY2 promoter is functional, and its activity could be enhanced by the HRE-1157 under hypoxic stimulation (n ¼ 4, **P , 0.01).
CNPY2 promotes angiogenesis condensation of vimentin towards one side of the cytoplasm, with the nucleus remaining in the centre. By 30 min, the vimentin was even more polarized in the cell. This CNPY2-induced dynamic redistribution of vimentin indicates that CNPY2 may promote the mobility of SMCs. In a scratch wound-healing assay, stimulation of SMCs by CNPY2 protein resulted in a nearly four-fold increase in cell migration after 15 h, compared with the vehicle control group ( Figure 3B) . Similarly, in a transwell migration assay, 5 h of stimulation with CNPY2 induced an approximately four-fold increase in the number of SMCs that had migrated towards the bottom of chamber where the CNPY2 protein was added, compared with vehicle control. Moreover, cultured SMCs were subjected to a proliferation assay, in which CNPY2 protein was added to stimulate the growth of SMCs every other day. As shown in Figure 3D , equal numbers of SMCs were seeded initially at Day 0, and However, from Day 3, slightly increased proliferation was seen and became more pronounced by Days 5 and 7 (n ¼ 3, **P , 0.01). (E) Cultured SMCs were stimulated with CNPY2 and counted. Starting from Day 3, an increased number of SMCs was seen in the CNPY2 group compared with vehicle control, and the difference became more noticeable by Days 5 and 7 (n ¼ 4, *P , 0.05 and **P , 0.01).
no effect was seen on Day 1. In contrast, starting from Day 3 onwards, a slight proliferative increase was shown by CNPY2-stimulated SMCs, which became more obvious by Day 7, compared with the vehicle control group. The absolute numbers of SMCs treated with CNPY2 or vehicle control were also counted at different days, and starting from Day 3, increased number of SMCs stimulated with CNPY2 was seen compared with the SMCs treated with vehicle control ( Figure 3E ).
CNPY2 activates Cdc42/PAK1/FAK in SMCs
To investigate the signalling pathways that are responsible for accelerated SMC migration, we used immunoprecipitation to isolate active Cdc42, Rac1, and Rho after stimulation of SMCs by CNPY2 protein.
As shown in Figure 4 , CNPY2 activated Cdc42 from 5 min after stimulation, peaking at 10 -30 min, and then gradually decreasing. On the other hand, CNPY2 did not activate Rac1or Rho, but instead may slightly inhibit them at later time points. Immediate and strong phosphorylation of PAK1 was seen in SMCs after only 5 min of stimulation by CNPY2, which lasted until 30 min and then decreased. Phosphorylation of FAK at Tyr 861 and Tyr 925 was nearly absent in unstimulated SMCs but became prominent after CNPY2 stimulation, peaking between 10 and 20 min. These data are consistent with the activation of PAK1 by Cdc42, as has been described previously. 17, 18 Changes of focal adhesion status, 19 a known role of the FAK and PAK1 kinases, may be the underlying molecular signalling events responsible for the accelerated SMCs contraction and migration triggered by CNPY2 protein.
CNPY2 stimulates ex vivo aortic sprouting and enhances neovascularity of the injured retina in vivo
The accelerated migration and proliferative effect of CNPY2 on SMCs led us to hypothesize that CNPY2 might play a role in angiogenesis.
To evaluate the biological effect of CNPY2 on vascularization, we employed an ex vivo assay with rat aortic rings grown in Matrigel and culture medium. As shown in Figure 5A , the aortic rings stimulated with CNPY2 protein showed a substantially greater area of microvessel sprouting ( 6-fold) compared with vehicle control. It appears that CNPY2 had a slightly higher sprouting area than the positive control VEGF, but the difference did not reach statistical significance. Surprisingly, as demonstrated in Figure 5B , a few a-SMA-positive SMCs were found among the cells that have migrated outside the aortic rings stimulated with CNPY2 protein, in addition to the ECs. In contrast, no a-SMA-positive SMCs but only ECs could be found outside the aortic rings stimulated with VEGF protein, indicating that CNPY2 might have a very different mechanism and a unique biological effect on SMCs. In addition, we employed a mouse retinal ischaemia/reperfusion injury model to assess the angiogenic effect of CNPY2 in vivo. CNPY2 protein (25 ng) was injected intravitreally immediately after injury, and 7 days later, isolectin IB4 staining revealed that CNPY2 stimulated an approximately two-fold increase in the area of the capillary network, vessel length, and new vessel branching, compared with saline control (Figure 6 ).
Discussion
We evaluated SMCs challenged by hypoxia and identified CNPY2 as a hypoxia-responsive transcript. We used ChIP-PCR to show that HIF-1a binds the first HRE (21157 bp upstream of the TSS) upstream of the predicted CNPY2 promoter. We also used luciferase reporters to show that this HRE cloned in front of the minimal promoter served as an 'enhancer' element upon hypoxia for HIF-1a binding, resulting in activation of the minimal promoter compared with the mutant HRE-1157 control. More convincingly, we also cloned this HRE-1157 followed by the endogenous human CNPY2 promoter region in a promoterless luciferase vector to assess native CNPY2 promoter activity. The data confirmed that the endogenous CNPY2 promoter was functional and could be enhanced by the presence of this HRE-1157 under hypoxic stimulation. CNPY2 is abundantly expressed in SMCs, along the classical secretory pathway from the ER to the Golgi, with secreted CNPY2 detected in human and mouse blood and in SMC culture medium. Hypoxia stimulation resulted in the HIF-1a-controlled activation of CNPY2 mRNA which in turn increased CNPY2 protein secreted into the culture medium. A secreted factor, CNPY2 enhanced in vitro SMC migration and proliferation, stimulated ex vivo aortic sprouting, and promoted increased revascularization of the injured mouse retina in vivo.
Taken together, these results show that CNPY2 encodes a previously unrecognized HIF-1a-regulated, secreted angiogenic growth factor. Interestingly, only CNPY2, but not VEGF, induced a few SMCs to migrate outside the aortic rings in the ex vivo assay, indicating that CNPY2 may have a unique biological effect on SMCs compared with other known angiogenic factors such as VEGF. Early angiogenesis requires ECs to form the capillary structure, but these vessels remain immature and unstable until supporting SMCs are recruited. 1 The specific effects of CNPY2 on SMCs may have unique biological influence on blood vessel maturation and stabilization, while VEGF-induced capillary formation tends to be unstable and leaky. 20, 21 In this study, we have focussed on the role of CNPY2 in SMCs. It remains possible that CNPY2 also plays an angiogenic role in ECs. We will explore this possibility in future work.
Our current results point to a role for CNPY2 in recruiting stabilizing SMCs to nascent angiogenic networks, which may be a specific role not shared by other important angiogenic factors, including VEGF. There are so far limited reports about CNPY2's biological function. CNPY2 was initially reported to be a putative type II transmembrane domain protein, named HP10390, 22 because a chimeric protein containing the CNPY2 N-signalling peptide fused to a cDNA fragment encoding the protease domain of urokinase-type plasminogen activator did not exert fibrinolytic activity, suggesting its N-signal peptide was not cleaved by signal peptidase. However, other predictions made in that study were later found to be incorrect, including one protein (HP10433) that was predicted to be a non-secreted type II transmembrane protein, but was later found to be the secreted retinoic acid receptor responder 2. 22 In another study, CNPY2 was found to co-purify with human hepatic lipase during its maturation in CHO cells treated with the reducing agent DTT, but not in untreated cells. However, as stated by these authors, CNPY2 was unlikely to function as an ER chaperon molecule for hepatic lipase, and its co-purification may have resulted from contamination. 23 The subcellular location and biological function of CNPY2 remained unclear from these previous studies. Human CNPY2 is 182aa in length, with an N-signal peptide (the first 20 amino acids) and no hydrophobic transmembrane domains, classical features of secreted proteins. 16 Intriguingly, CNPY2 also possesses an ER-retrieval signal (HDEL) at its C-terminal end. Such sequences are usually recognized by KDEL receptors and hold the protein exclusively in the ER compartment, preventing secretion. 24 Here, we showed that CNPY2 co-localized not only with ER but also with the Golgi. Most importantly, secreted CNPY2 protein was detected in human and animal blood and in the culture medium of SMCs both by a commercial ELISA kit and by a direct pull-down of natively secreted CNPY2 protein present in SMC culture medium with our own CNPY2 antibody. 12 The presence of CNPY2 protein in the Golgi compartment, and secreted CNPY2 in the medium of cultured ECs and in the blood of healthy humans and animals, indicates that this 'HDEL' retrieval peptide may not be fully functional, and instead perhaps serves as a quality control system to balance the amount of intracellular vs. secreted CNPY2.
Under certain condition such as hypoxia, when increased CNPY2 mRNA production is driven by HIF-1a, overexpressed CNPY2
protein molecules may saturate all the available KDEL receptors and result in more protein secretion. We show that, in contrast to its predicted functions, CNPY2 is a secreted protein.
Angiogenesis is an adaptive response to hypoxia, and HIF-1a, with its unique hypoxia-responsive activation, is a key factor required to induce revascularization after ischaemic injury. 25 Other angiogenic factors are also known to be transcriptionally regulated by HIF-1a, including VEGF. 26 Our identification of CNPY2 as a novel, HIF-1a-regulated, angiogenic secreted factor brings up many questions about the containing either CNPY2 or VEGF recombinant proteins to explore the role of CNPY2 in angiogenesis. The aortic rings stimulated with CNPY2 showed a substantially greater area of microvessel sprouting ( 6-fold) compared with vehicle control (n ¼ 4, **P , 0.01). A known angiogenic factor, VEGF, was used as a positive control. The CNPY2 group had a slightly higher sprouting area than VEGF, but the difference did not reach statistical significance. The sprouting area was quantified and expressed as relative fold change compared with vehicle control. Scale bar ¼ 500 mm. (B) Representative micrographs showing cells that had migrated from the aortic rings stimulated with CNPY2 or VEGF. Whole Matrigels containing the aortic rings were fixed, paraffin-embedded, sectioned, and stained with a-SMA (green) for SMCs, Factor VIII (FVIII, red) for ECs and DAPI (blue) for nuclei. The majority of cells induced to migrate outside the aortic rings by both CNPY2 and VEGF were ECs. The thin endothelium (red) along the inner side of the aortic rings served as positive control for FVIII staining (arrows), and multiple lays of SMCs inside the aortic rings (green) showed specific staining for a-SMA.
No a-SMA-positive SMCs could be found in VEGF-induced rings, but a few a-SMA-positive SMCs (green) were identified in the rings that were stimulated with CNPY2 (n ¼ 4, scale bar ¼ 50 mm).
CNPY2 promotes angiogenesis overlapping and independent roles of these angiogenic factors in development as well as in revascularization after ischaemia. VEGF has been explored for gene therapy to induce beneficial angiogenesis after cardiac injury. 27 Since we show that CNPY2 functions as well or better than VEGF in an ex vivo assay for angiogenesis, CNPY2 should also be explored as an alternative therapy after a myocardial infarction. However, significant further work is required to characterize this novel factor, including examining the effect of CNPY2 on ECs and on other relevant cell types and tissues. These investigations are beyond the scope of this report, although a direct biological effect of CNPY2 on ECs can be inferred from our ex vivo aortic sprouting and in vivo retina revascularization assays. In addition, the cell surface receptor(s) that CNPY2 binds to deliver the angiogenic signal also warrants future investigation.
In conclusion, our study shows that CNPY2 encodes a new secreted angiogenic growth factor controlled by HIF-1a, which may be important for SMC proliferation and may provide a unique target to induce revascularization after tissue injury. Figure 6 CNPY2 revascularizes the injured retina. A mouse retinal ischaemia/reperfusion injury model was used to assess the angiogenic effect of CNPY2 in vivo. CNPY2 protein (25 ng) was injected intravitreally immediately after the injury, and 7 days later, the capillary structure was stained with isolectin IB4 (bright staining). Whole retinal images (top) and enlarged images (bottom) are shown. CNPY2 protein stimulated an approximately two-fold increase in total capillary network area, vessel length, and new vessel branching, compared with non-injured controls (n ¼ 3, *P , 0.05 and **P , 0.01). Scale bar ¼ 1 mm for the whole retinae and 100 mm for the enlarged area.
